about
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAARTSurvival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter studyChronic cryptococcal meningitis in an intravenous drug addict without evidence of infection by HIV-1,2 in southern Italy.Limiting severe outcomes and impact on intensive care units of moderate-intermediate 2009 pandemic influenza: role of infectious diseases units.Incidence, timing, and determinants of bacterial pneumonia among HIV-infected patients: data from the ICONA Foundation Cohort.Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature.The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort studyTiming of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort.HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trialPrevalence of Plasmodium spp. in malaria asymptomatic African migrants assessed by nucleic acid sequence based amplificationItalian consensus statement on management of HIV-infected individuals with advanced disease naïve to antiretroviral therapy.Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study groupChlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus.Targeted therapies in hepatocellular carcinoma.Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT).Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study.Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns.The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antPrevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.The biological phenotype of HIV-1 is usually retained during and after sexual transmission.Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.Chronic inflammation in a long-term cohort of HIV-infected patients according to the normalization of the CD4:CD8 ratio.Identification of a new HIV-1 BC circulating recombinant form (CRF60_BC) in Italian young men having sex with men.Does HIV-1 co-receptor tropism correlate with fibrosis progression in HIV/HCV co-infected patients?Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.Late presentation and loss to follow-up of immigrants newly diagnosed with HIV in the HAART era.Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy.Peginterferon alfa-2b treatment for patients affected by acute hepatitis C: presentation of six case reports.Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection.Are the proposed env mutations actually associated with resistance to maraviroc?Co-receptor switch during HAART is independent of virological success.Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years.Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy.Parkinsonism in a patient with AIDS and cerebral opportunistic granulomatous lesions.Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen).
P50
Q28476094-C3BD9F80-842F-4AB3-95FD-788B7C225414Q28538165-812E5090-CFDA-42AE-A628-8E33E38C7F51Q30417872-1468564E-13F6-48A8-A93D-436FCFD52E1CQ30420451-C0381ED2-DC4A-4FEB-9157-D405C81F761CQ30617407-79890034-04B1-4823-BB8F-0B14C30D3F5DQ33682067-333C513E-90AF-4072-85A4-B4510DEA5D7EQ33864926-A2261ACE-E8E5-4398-98B5-3D84EDD98372Q35108221-04EED7D8-8CC8-4438-B711-BBC56623C29FQ35552889-7FE9BA86-B795-480B-AA93-2350B64E83A9Q37081227-3D76FCF7-7936-48AB-A121-870B8DDFA052Q37500009-8439D318-AE08-42D5-8329-4BEC62256CEAQ37530942-65275172-EF0D-4BF0-892B-EABF1CE10A3CQ37881880-B4E9A600-1006-44BA-A873-D0207DE88994Q38132872-A79D41A4-448D-4E1F-B164-E9FA8C019230Q38226627-CD8B584E-502F-4614-A45E-70A8CAE786F4Q38425305-49ADEB59-5AF6-4E19-9FF3-DE53D0E55190Q38554626-1840B7C2-120C-4D80-B578-AB7E8F835976Q38932602-FCFF00D8-AB66-4DF5-8DEC-FE1DA03F8E37Q39000397-2F5F10F2-C616-4418-99EB-8BAD00BAAF5DQ39015989-B5CA54EA-DB79-45A0-A1BC-F18F6998FAE4Q39429683-44239348-3647-487C-A4D9-CC56669E4342Q39530566-1F82F589-1334-41FB-A9CE-1C7A716C5442Q40396257-A550D13D-69E8-4A8D-A558-8C5D8F173FC5Q41436915-0A3C7C42-AA2B-44DC-B33C-621B921ECCA1Q41590727-6078B4BE-FE28-4CC0-A010-6EEC0A126EA7Q41682247-E8A4CC10-0518-48EA-ACE3-1F7529BC57E9Q42225354-4EDE8DD1-9568-428B-94EB-522AC1BC7E72Q42231422-8FBB2820-9308-4ABE-B745-AFB7D556A5CEQ42232261-37EDA560-534A-4E52-9110-681AB5741DCEQ42251208-206AF77E-E37C-47DE-AA92-7786CDFA38ACQ42287905-F2C04CD7-A4EC-4D62-BD3B-93AF5FC41D6CQ42991113-D3129B5A-BC50-4CC2-B1D1-843692A97111Q42993837-421A19B4-AACE-49CA-8B3F-DB337944DF09Q43134606-40601992-CC86-4111-B536-E405F6F37CFDQ43255080-2656AD54-8249-426B-A01E-3B20AE2500C9Q43848591-D4C2E0A4-8D18-47F3-8ADE-A172413F23E8Q43895183-674A29D5-6B69-461A-BCDD-97F165EE8A25Q44314941-1D99C5CF-F985-4E01-A616-CCBA697170EDQ44414087-7A0B7F6D-FF25-451B-8DE0-DFDB8ACC1EA8Q45172102-8B78D4E8-B4BE-47CC-861F-1E9C1ECFD61D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gioacchino Angarano
@ast
Gioacchino Angarano
@en
Gioacchino Angarano
@es
Gioacchino Angarano
@nl
type
label
Gioacchino Angarano
@ast
Gioacchino Angarano
@en
Gioacchino Angarano
@es
Gioacchino Angarano
@nl
altLabel
Gioacchino ANGARANO
@en
prefLabel
Gioacchino Angarano
@ast
Gioacchino Angarano
@en
Gioacchino Angarano
@es
Gioacchino Angarano
@nl
P106
P1153
7007111846
P31
P496
0000-0003-3207-7523